Multiple Sclerosis explores the new pavillion Turns out, I AM a Barbie girl. If Barbie was a perpetually confused, middle aged woman with a slight attitude, MS, and a ton of fatigue. And sneakers. None of those little, pink, plastic heals for me, thank you very much. Actually, this multiple sclerosis blog has nothing to…
AAN 2026: Ocrevus preserves walking, hand function in early RRMS
First-line treatment with Ocrevus (ocrelizumab) preserved walking abilities and hand function in most people with early relapsing-remitting multiple sclerosis (RRMS) over six years, according to data from a Phase 3b clinical trial and its extension study. The findings were presented in a talk by Robert Bermel, MD, of the Cleveland Clinic, at the American Academy…
My husband’s MS diagnosis changed everything — and nothing
I had never known anyone personally who had been admitted to a psychiatric hospital. Walking my husband, Rhead, through those doors was one of the strangest moments of my life — not strange in a dramatic way, but strange in the quiet, disorienting way of realizing your life has become something you could not have…
Empowering Myself
I have realized that every time I go to a doctor’s appointment, I walk in already feeling guilty — mentally preparing to defend myself, almost expecting judgment. Before the doctor starts asking about my exercise routines and eating habits, I … Continue reading → Source: blog.mymsaa.org
AAN 2026 The First BTK inhibitor for PPMS to Make-It?
Tweet So it looks like Fenebrutinib may make it where other BTK inhibiotrs has so far failed. The drug inibits relapsing and primary progressive MS in regard to primary progressive MS it is no worse than ocrelizumab and make be a little better. The main difference between fenebrutinib and the past failures are that it…
The price of healing should not be debt
There are moments when living with Multiple Sclerosis feels like a series of calculations between what we can afford, what can wait, and what simply cannot happen at all. Dan recently faced one of those moments when he needed hernia surgery. It wasn’t optional, and it wasn’t related to his MS. But like so many…
Frexalimab AAN20226
Tweet Frexalimab is an indirect B cell inhibitor. It block the natural signal that a B cell gets from T cells and antigen presenting cells as it blocks the ligand (binding bit) to the CD40 receptor. This receptor needs to be stumulated at the same time as the antigen receptor for B cells to be…
AAN-2026 O-HAND hits its endpoint
Tweet We recently had a post where the FDA was starting to question the data from the ORATORIO trial and British Medical Journal suggested that the data was fudged and that the women in the trial got no/less efficacy and that they got a risk of breast cancer which had occurred in the trial. I…
Enrollment complete in Phase 3 trial of at-home Briumvi injection for MS
Patient enrollment is complete in a Phase 3 trial testing a new formulation of Briumvi (ublituximab-xiiy), TG Therapeutics‘ multiple sclerosis (MS) medication for relapsing forms of the disease, that could be injected at home. The new formulation is designed to be given under the skin, or subcutaneously, every two or three months, which could offer a…
La vida se disfruta más fuera del piloto automático
Me considero una persona rutinaria. Tengo la tendencia natural de apegarme a las rutinas que funcionan, y me resulta difícil modificarlas una vez que se vuelven cómodas. Si bien las rutinas pueden ser útiles, en ocasiones hacen que la vida … Continue reading → Source: blog.mymsaa.org